POD | ||||
---|---|---|---|---|
Complications | CDC grade | Management | 0–30 | 0–90 |
n (%) | n (%) | |||
Gastrointestinal | 126 (26.9) | 145 (27.8) | ||
Ileus (paralytic) | 1 | Conservative | 19 (4) | 20 (3.8) |
2 | Replacement of nasogastric tube | 12 (2.5) | 17 (3.2) | |
3b | Laparotomy | 6 (1.2) | 13 (2.4) | |
Small bowel obstruction (mechanical) | 3b | Laparotomy | 2 (0.4) | 2 (0.3) |
Constipation | 1 | Conservative | 14 (2.9) | 15 (2.8) |
GIS bleeding | 2 | Blood transfusion | 6 (1.2) | 6 (1.1) |
Emesis | 1 | Conservative | 53 (11.3) | 57 (10.9) |
Anastomotic bowel leakage | 3b | Laparotomy | 4 (0.8) | 4 (0.7) |
Diarrhea | 1 | Conservative | 10 (2.1) | 11 (2.1) |
Infectious | 56 (11.9) | 65 (12.4) | ||
Fever of unknown | 2 | Conservative | 26 (5.5) | 28 (5.3) |
Lower urinary tract infection | 2 | Antibiotic treatment | 16 (3.4) | 17 (3.2) |
Abscess | 2 | Antibiotic treatment | 4 (0.8) | 5 (0.9) |
3a | Incision and drainage | 2 (0.4) | 4 (0.7) | |
3b | Incision and drainage (under general anesthesia) | 1 (0.2) | 3 (0.5) | |
Sepsis | 2 | Antibiotic treatment | 2 (0.4) | 2 (0.3) |
4b | Multiorgan dysfunction | 3 (0.6) | 4 (0.7) | |
Pyelonephritis | 2 | Antibiotic treatment | 1 (0.2) | 1 (0.1) |
Cholecystitis | 3b | Cholecystectomy | 1 (0.2) | 1 (0.1) |
Wound | 24 (5.1) | 26 (4.9) | ||
Wound seroma | 1 | Conservative | 6 (1.2) | 7 (1.3) |
Wound dehiscence (fascia intact) | 2 | Antibiotic treatment and saturation under local anesthesia | 6 (1.2) | 7 (1.3) |
Evisceration | 3b | Secondary surgical closure | 12 (2.5) | 12 (2.2) |
Genitourinary | 52 (10.9) | 63 (12) | ||
Acute kidney injury | 1 | Conservative | 40 (8.4) | 50 (9.4) |
4a | Dialysis | 5 (1) | 5 (0.9) | |
Urinary leak/urinoma | 3b | Ureteral reimplantation | 1 (0.2) | 1 (0.1) |
Incisional hernia | 3b | Laparotomy and surgical revision | 3 (0.6) | 3 (0.5) |
Urostomy ischemia | 1 | Conservative | 0 | 1(0.1) |
3b | Laparotomy | 1 (0.2) | 1 (0.1) | |
Hematuria | 1 | Conservative | 2 (0.4) | 2 (0.3) |
Cardiac | 20 (4.2) | 20 (3.8) | ||
Arrythmia | 2 | Conservative, medical treatments | 2 (0.4) | 2 (0.3) |
Myocardial infarction | 4a | Coronary angiography stent | 2 (0.4) | 2 (0.3) |
Hypertension | 2 | Medical treatment | 2 (0.4) | 2 (0.3) |
Angina | 1 | Conservative | 2 (0.4) | 2 (0.3) |
Hypotension | 2 | Medical treatment | 12 (2.5) | 12 (2.3) |
Pulmonary | 23 (4.9) | 23 (4.4) | ||
Pneumonia | 2 | Antibiotic | 4 (0.8) | 4 (0.7) |
Dyspnea | 1 | Oxygen treatment | 19 (4) | 19 (3.6) |
Bleeding | 23 (4.9) | 28 (5.3) | ||
Anemia req. transfusion | 2 | Blood transfusion | 23 (4.9) | 28 (5.3) |
Thromboembolic | 7 (1.4) | 9 (1.7) | ||
Deep vein thrombosis | 2 | Anticoagulants | 6 (1.2) | 8 (1.5) |
Pulmonary emboli | 2 | Anticoagulants | 1 (0.2) | 1 (0.1) |
Neurological | 19 (4) | 20 (3.8) | ||
CVA-TIA | 2 | Antiplatelet/anticoagulant | 10 (2.1) | 11 (2.1) |
Delirium | 2 | Antipsychotic | 9 (1.9) | 9 (1.7) |
Miscellaneous | 111 (23.7) | 113 (21.6) | ||
Prolonged lymphatic drainage (> 11 days) | 1 | Conservative — clinical observation | 111 (23.7) | 113 (21.6) |
Death | 6 (1.2) | 9 (1.7) | ||
Sepsis | 5 | 1 (0.2) | 3 (0.5) | |
Acute kidney failure | 5 | 0 | 1 (0.1) | |
Ventricular fibrillation | 5 | 1 (0.2) | 1 (0.1) | |
Disseminated Intravascular coagulation | 5 | 1 (0.2) | 1 (0.1) | |
Electrolyte disorders | 5 | 2 (0.4) | 2 (0.3) | |
Aspiration pneumonia | 5 | 1 (0.2) | 1 (0.1) | |
Total | 467 (100) | 521 (100) |